Xenogen Corp.

News & Analysis

xenogen corp. - All News and Analysis

• Xenogen IVIS Spectrum.(CLOSE UP: Imaging)

  - 2007-05-01

  The Xenogen IVIS Spectrum is a flexible addition to the company's suite of in vivo imaging systems that performs high-sensitivity bioluminescent imaging and advanced fluorescent imaging, and includes spectral unmixing, trans-illumination and 3-D tomographic capabilities. With an optical switch to move from epi- (reflection or...

  Tags: Xenogen Corp.

• Caliper Life Sciences launched the Discovery Alliances & Services unit, created by the integration of NovaScreen Biosciences, a provider of in vitro discovery services, and Xenogen Biosciences, a provider of in vivo discovery services

  - 2007-04-30

  Caliper Life Sciences launched the Discovery Alliances & Services unit, created by the integration of NovaScreen Biosciences, a provider of in vitro discovery services, and Xenogen Biosciences, a provider of in vivo discovery services. It offers more than 700 in vitro assay types.

  Tags: Xenogen Corp.

• Zacks Analyst Blog Highlights: Caliper, Xenogen, Digitas, General Motors and Best Buy

  - 2006-07-20

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day, the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Caliper (Nasdaq: CALP), Xenogen (Nasdaq: XGEN), Digitas (Nasdaq: DTAS), General Motors...

  Tags: Best Buy Co. Inc., blog, Caliper, General Motors Corp., Nasdaq Stock Market Inc.

• Caliper Life Sciences to acquire Xenogen for $80 million

  - 2006-02-15

  Hopkinton, MA and Alameda, CA 2//3/06--Caliper Life Sciences and Xenogen have announced a definitive merger agreement under which Caliper will acquire all Xenogen outstanding equity securities for $80 million in Caliper issued common stock and warrants. Xenogen shareholders will own approximately 26% of Caliper's outstanding common stock and approximately 32%...

  Tags: Xenogen Corp.

• Caliper Life Sciences Acquisition of Xenogen Conference Call - Research and Markets Offers a Transcript of 'Caliper Life Sciences' Conference Call

  - 2006-02-14

  DUBLIN, Ireland -- The Caliper Life Sciences (NASDAQ:CALP) Corporate Conference Call took place on 13-Feb-06 9:00am ET. CALP announced on 02/13/2006 its intent to acquire Xenogen Corporation. The combination is structured as an all-stock transaction, and CALP will issue 13.2m common shares plus 5.125m warrants in exchange for all...

  Tags: Xenogen Corp.

• Xenogen Launches First Commercial Three-Dimensional Biophotonic Imaging System.

  - 2005-09-07

  ALAMEDA, California, September 7 /PRNewswire/ -- - System Is Designed to Provide Researchers With Better Data Earlier in the Drug Discovery Process Xenogen Corporation (Nasdaq: XGEN) announced today the launch of its IVISR 3D Imaging System, the first commercial three-dimensional ...

  Tags: Xenogen Corp.

• Xenogen

  - 2005-06-30

  Affymetrix Senior Vice President and CFO Gregory T. Schiffman and Caliper Life Sciences CEO E. Kevin Hrusovosky joined the board of biophotonic imaging company Xenogen.

  Tags: Xenogen Corp.

• Xenogen IPO cut attracts buyers

  - 2004-07-17

  ALAMEDA -- Biotechnology firm Xenogen's decision to cut its initial public offering price brought in the buyers on its first day of trading Friday, with the share price closing up 7 percent. The Alameda-based company, which raised $29.4 million in the IPO, sold 4.2 million shares at...

  Tags: Xenogen Corp.

• Xenogen Corporation Announces Initial Public Offering

  - 2004-07-16

  ALAMEDA, Calif. -- Xenogen Corporation (Nasdaq: XGEN) announced today the initial public offering of 4,200,000 shares of common stock at a price of $7.00 per share. All of the shares are being sold by the Company. The Company has granted the underwriters an option to purchase an additional 630,000 shares...

  Tags: Company, FINANCE, Investment, IPO, Nasdaq Stock Market Inc.

• Charles River Laboratories Collaborates with Xenogen Biosciences in Strategic Marketing Agreement

  - 2003-04-07

  Business Editors/Health/Medical Writers BIOWIRE2K WILMINGTON, Mass.--BUSINESS WIRE--April 7, 2003 - Services to Speed Availability of Genetically-Modified Research Models - Charles River Laboratories International, Inc. (NYSE:CRL), a leading provider of pre-clinical research products and services to biopharmaceutical and biotechnology companies, and Xenogen Biosciences, a wholly-owned subsidiary...

  Tags: Charles River Laboratories Inc., Company